#mrna | BlueJet Consulting

RSS feed

COVID-19 to reshape R&D investments toward infectious diseases

Infectious diseases have been largely forgotten by Pharma R&D and investors, as chronic diseases, cancer and rare diseases gave better...

Covid-19 vaccine approval to massively accelerate mRNA innovation

With COVID-19 vaccine authorization, BioNTech SE and Pfizer open the door for massive acceleration of mRNA innovation, in...

Moderna Covid-19 vaccine: 94% efficacy with easier storage

Following Pfizer-BioNTech 90% efficacy announcement, Moderna data show 94% efficacy against Covid-19, while allowing easier storage: long...